AEON Biopharma

AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing ABP-450 (Botulinum Toxin Type A) injection for the treatment of debilitating conditions. AEON Biopharma initially concentrates on the neurology and gastroenterology markets. The company is committed to innovating in the rapidly expanding therapeutic botulinum toxin market and believes that AEON Biopharma can provide patients with safe and effective treatment options while offering differentiated economic benefits to consumers, patients, and physicians.